Novartis presented study data at the?American Heart Association's (AHA) scientific sessions showing that?Entresto (sacubitril/valsartan) outperformed enalapril in patients with heart failure with reduced ejection fraction requiring hospitalisation for an
Novartis presented study data at the?American Heart Association's (AHA) scientific sessions showing that?Entresto (sacubitril/valsartan) outperformed enalapril in patients with heart failure with reduced ejection fraction requiring hospitalisation for an